BOSTON--(BUSINESS WIRE)--Alivio Therapeutics, an affiliate of PureTech Health plc (LSE: PRTC) developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense (DoD) Technology/Therapeutic Development Award to advance Alivio’s product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) with Hunner’s lesions. The funds will support Alivio’s preclinical research and development activities, including GMP manufacturing, to enable the filing of an investigational new drug (IND) application for ALV-107.
Alivio’s inflammation-targeting technology is designed to administer therapeutics to the sites of inflammation, while sparing healthy tissue. The technology is also engineered to respond dynamically to inflammation, releasing the entrapped therapeutics based on the degree of inflammation present. This approach is being evaluated across a variety of diseases, including IC/BPS, pouchitis, and inflammatory bowel disease (IBD).
J. Curtis Nickel, M.D. FRCSC, Professor, CIHR Canada Research Chair in Urologic Pain and Inflammation at Queen’s University said, “Interstitial cystitis is one of the most important unmet needs in urology. New therapies that can offer long-lasting relief from the pain associated with the disease would make a major impact in the lives of patients. I am hopeful that this award will accelerate development of this potentially new therapy for interstitial cystitis/bladder pain syndrome and look forward to seeing ALV-107’s impact in the clinic.”
“Our inflammation-targeting technology approach has the potential to treat a range of chronic and acute inflammatory disorders, such as interstitial cystitis/bladder pain syndrome with Hunner’s lesions, that would otherwise be difficult to treat,” said Eric Elenko, Ph.D., PureTech’s Chief of Strategy and Research and Alivio Co-founder. “ALV-107 could potentially offer a novel therapeutic option to improve the health of patients living with this devastating disease, and this award will help to support our effort to advance ALV-107 towards the clinic.”
Alivio’s platform technology has demonstrated proof-of-concept in ten different preclinical models of inflammation including a validated preclinical model for the treatment of IC/BPS. ALV-107 showed durable pain control throughout a 24-hour study period in this model of IC/BPS, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg). Beyond ALV-107, Alivio is advancing additional product candidates to enable new immunomodulatory therapies and active pharmaceutical ingredients (APIs), including biologics, and nucleic acids for inflammatory conditions of the GI tract and other parts of the body.
About Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and
Hunner’s Lesions
Interstitial Cystitis or Bladder Pain Syndrome
(IC/BPS) is a chronic bladder condition that consists of discomfort or
pain in the bladder or surrounding pelvic region and is often associated
with frequent urination. It is estimated to affect up to 12 million
people in the U.S. and is more common in women than men. Current
treatments fail to control pain in many patients, particularly patients
with Hunner’s lesions, which are estimated to affect 5-10% of IC/BPS
patients in the U.S.
About the U.S. Department of Defense Award
The U.S. Army
Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick
MD 21702-5014 is the awarding and administering acquisition office. This
work is supported by the Office of the Assistant Secretary of Defense
through the Peer Reviewed Medical Research Program under Award No.
W81XWH-18-1-0566. Opinions, interpretations, conclusions and
recommendations are those of the author and are not necessarily endorsed
by the Department of Defense.
About Alivio
Alivio Therapeutics, Inc., an affiliate of
PureTech Health (PRTC.L), is pioneering targeted disease
immunomodulation as a novel strategy to treat a range of chronic and
acute inflammatory disorders. Targeted disease immunomodulation involves
tuning the immune system exclusively at the site of disease in the body,
with minimal impact on the rest of the immune system. This long
sought-after approach has potential to treat a range of chronic and
acute inflammatory disorders including ones that would otherwise be
difficult to treat. Based on the research of Dr. Karp and Dr. Robert
Langer, David H. Koch Institute Professor at MIT, Alivio’s proprietary
inflammation-targeting platform is designed to administer therapeutics
to the sites of inflammation, while sparing healthy tissue. The
technology is also engineered to respond dynamically to inflammation,
releasing the entrapped therapeutics based on the degree of inflammation
present. Alivio’s pipeline includes candidates for interstitial
cystitis/bladder pain syndrome (IC/BPS), pouchitis, and inflammatory
bowel disease (IBD).
The technology platform has been published in peer-reviewed journals, including in Science Translational Medicine and Nature Communications, and the technology is the first of its kind to demonstrate reproducible targeting of immunomodulatory compounds to inflamed tissue in preclinical models, having been validated in multiple labs and in ten different preclinical models of inflammation where the inflammation occurred in different parts of the body (e.g., the GI system, the bladder, joints, skin, etc.). The technology could potentially be used with a variety of medications (e.g., small molecules, biologics, and nucleic acids) both independently or in combination and is designed to be administered orally or via other routes. With this platform, Alivio aims to address the dozens of conditions where inflammation is a central part of the underlying disease pathology, but where targeted and effective treatment options are lacking.
Alivio is developing its therapies in collaboration with several of the world’s leading experts in biomaterials and immunology. Expert advisors include: Jeffrey Karp, Ph.D., Professor of Medicine at Brigham and Women’s Hospital and Alivio co-founder; Robert Langer, Sc.D., Alivio co-founder and Non-Executive Director at PureTech Health and David H. Koch Institute Professor at MIT; Michael B. Brenner, MD, Chief of the Division of Rheumatology, Immunology and Allergy at BWH; Ulrich H. von Andrian, M.D., Ph.D., Mallinckrodt Professor of Immunopathology at Harvard Medical School; and Ralph Weissleder, M.D., Ph.D., Director of the Center for Systems Biology at Massachusetts General Hospital.
